Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

Hiroshi Ureshino, Naoto Takahashi, Takayuki Ikezoe, Ayako Takamori, Atsushi Kawaguchi, Tatsuo Ichinohe, Shinya Kimura

Blood (2023) 142 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2023-174594

Published: 2023

Journal Articles

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Naoko Hosono, Takahiro Yamauchi, Chi Sung-Gi, Hironori Arai, Kentaro Fukushima, Daisuke Ikeda, Satoshi Iyama, Akihiko Gotoh, Takayuki Ikezoe, Chikashi Yoshida, Goichi Yoshimoto, Junya Kanda, Naoto Takahashi, Emiko Sakaida, Kensuke Usuki, Yosuke Minami

Blood (2023) 142 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2023-184546

Published: 2023

Journal Articles

Delivery of α-Particles By a Human-Rat Chimeric CD82 Monoclonal Antibody Potently Inhibits the Proliferation of CD82-Expressing Acute Myeloid Leukemia Cells in a Murine Xenograft Model

Takayuki Ikezoe, Taro Tachibana, Chiaki Hata, Cai-Xia Wang, Daisuke Koyama, Noboru Oriuchi, Ken-ichi Nishijima, Naoyuki Ukon, Saki Shimoyama, Taiki Joho, Kohshin Washiyama, Kazuhiro Takahashi, Songji Zhao

Blood (2023) 142 (Supplement 1): 2794.

https://doi.org/10.1182/blood-2023-174676

Published: 2023

Journal Articles

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Shinya Kimura, Kensuke Usuki, Tatsuo Ichinohe, Takayuki Ikezoe, Junya Kuroda, Senji Kasahara, Sho Okamoto, Hiromitsu Iizuka, Hiroshi Ureshino, Tatsuro Watanabe, Tokihiro Ro, Kosuke Endo, Yuka Kagawa, Yuki Kurahashi, Toshiki Naito, Takahiro Yamauchi

Blood (2023) 142 (Supplement 1): 6466.

https://doi.org/10.1182/blood-2023-173174

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda

Blood (2022) 140 (Supplement 1): 3371–3372.

https://doi.org/10.1182/blood-2022-167674

Published: 2022

Journal Articles

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Blood (2022) 140 (Supplement 1): 10722–10724.

https://doi.org/10.1182/blood-2022-159351

Published: 2022

Journal Articles

Attempts to Induce t(11;14) during Redifferentiation of Normal B Cell-Derived Ips Cells to Study Myeloma-Initiating Cells

Naohiro Tsuyama, Misaki Takahashi Sugai, Ken-ichi Kudo, Yusuke Azami, Megumi Sasatani, Kenji Kamiya, Takayuki Ikezoe, Masafumi Onodera, Akira Sakai

Blood (2022) 140 (Supplement 1): 12471–12472.

https://doi.org/10.1182/blood-2022-158655

Published: 2022

Journal Articles

Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells

Ken-ichi Kudo, Naohiro Tsuyama, Misaki Takahashi Sugai, Yusuke Azami, Miwa Fukami, Yu Abe, Akinobu Ota, Karnan Sivasundaram, Moe Muramatsu, Megumi Sasatani, Yuko Hashimoto, Shigehira Saji, Kenji Kamiya, Ichiro Hanamura, Takayuki Ikezoe, Masafumi Onodera, Akira Sakai

Blood (2021) 138 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2021-149108

Published: 2021

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Clinical Significance of Small PNH-Type Cell Populations in Bone Marrow Failure Syndromes - an Interim Analysis of Japanese Multicentrer Prospective Study -

Yasutaka Ueda, Kohei Hosokawa, Ken Ishiyama, Hiroyuki Takamori, Yuji Yonemura, Naoshi Obara, Hideyoshi Noji, Kiyoshi Ando, Tsutomu Shichishima, Takayuki Ikezoe, Shigeru Chiba, Haruhiko Ninomiya, Tatsuya Kawaguchi, Jun-ichi Nishimura, Yuzuru Kanakura, Shinji Nakao

Blood (2021) 138 (Supplement 1): 1122.

https://doi.org/10.1182/blood-2021-146353

Published: 2021

Journal Articles

Chromosomal Translocation t(11;14) Induced By the Cre-Loxp System in Normal B Cell-Derived Ips Cells for the Study of Myeloma-Initiating Cells

Misaki Sugai, BS, Naohiro Tsuyama, PhD, Yu Abe, PhD, Yusuke Azami, MD, Kenichi Kudo, PhD, Akinobu Ota, PhD, Sivasundaram Karnan, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134572

Published: 2020

Journal Articles

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Yasuyoshi Morita, Takayuki Ikezoe, MD PhD, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, MD PhD, Naoko Hosono, MD PhD, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, MD PhD, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, MD PhD, Masahiro Kizaki, MD, Koichi Akashi, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134078

Published: 2020

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

Journal Articles

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Keiji Minakawa, Koki Ueda, MD PhD, Osamu Nakajima, Tetsuro Yokokawa, MD, Yusuke Kinishima, MD, Tomofumi Misaka, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yasuchika Takeishi, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2019) 134 (Supplement_1): 2964.

https://doi.org/10.1182/blood-2019-124575

Published: 2019

Journal Articles

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Misaki Sugai, BS, Yu Abe, PhD, Yusuke Azami, MD, Yukari Yanai, MS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2019) 134 (Supplement_1): 3057.

https://doi.org/10.1182/blood-2019-122344

Published: 2019

Journal Articles

HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Keiji Minakawa, Koki Ueda, MD PhD, Akiko Shichishima, MD PhD, Hiroshi Ohkawara, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD, Yayoi Shikama, MD PhD, Kenneth E Nollet, MD PhD, Kazuhiko Ikeda, MD PhD

Blood (2018) 132 (Supplement 1): 4384.

https://doi.org/10.1182/blood-2018-99-114399

Published: 2018

Journal Articles

A Critical Role of Growth Arrest-Specific Gene 6-Mer Axis in the Pathogenesis of Endothelial Damage Contributing to Thrombotic Microangiopathy Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Miki Furukawa, MD PhD, Wang Xintao, MD PhD, Hiroshi Ohkawara, MD PhD, Masahiko Fukatsu, MD, Lobna Alkebsi, PhD, Hideyoshi Noji, MD PhD, Kazuei Ogawa, MD PhD, Takayuki Ikezoe, MD PhD

Blood (2018) 132 (Supplement 1): 4520.

https://doi.org/10.1182/blood-2018-99-112816

Published: 2018

Journal Articles

Attempt to Prove the Existence of Abnormal B Lymphocyte As Myeloma-Initiating Cells from B Cell-Derived Induced Pluripotent Stem Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Yukari Yanai, MS, Yu Abe, PhD, Misaki Sugai, BS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2018) 132 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2018-99-112759

Published: 2018

Journal Articles

The C Loop of Fifth Epidermal Growth Factor-like Domain of Thrombomodulin Exerts Cytoprotective and Angiogenic Effects in Vitro and In Vivo

Xiangmin Wang, Bin Pan, MD, Goichi Honda, PhD, Yuko Hashimoto, Hiroshi Ohkawara, MD PhD, Kailin Xu, MD, PhD, Lingyu Zeng, MD,PhD, Takayuki Ikezoe, MD, PhD

Blood (2017) 130 (Supplement 1): 2298.

https://doi.org/10.1182/blood.V130.Suppl_1.2298.2298

Published: 2017

NARROW

Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial

Practical and Flexible Genome Profiling Study Using the Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System: HM-Screen-JAPAN02

Delivery of α-Particles By a Human-Rat Chimeric CD82 Monoclonal Antibody Potently Inhibits the Proliferation of CD82-Expressing Acute Myeloid Leukemia Cells in a Murine Xenograft Model

An Open-Label, Multicenter, Single-Arm, Phase I Dose Escalation Study of OP-2100, an Orally Bioavailable Prodrug of Decitabine, for Patients with Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Attempts to Induce t(11;14) during Redifferentiation of Normal B Cell-Derived Ips Cells to Study Myeloma-Initiating Cells

Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Clinical Significance of Small PNH-Type Cell Populations in Bone Marrow Failure Syndromes - an Interim Analysis of Japanese Multicentrer Prospective Study -

Chromosomal Translocation t(11;14) Induced By the Cre-Loxp System in Normal B Cell-Derived Ips Cells for the Study of Myeloma-Initiating Cells

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

A Critical Role of Growth Arrest-Specific Gene 6-Mer Axis in the Pathogenesis of Endothelial Damage Contributing to Thrombotic Microangiopathy Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Attempt to Prove the Existence of Abnormal B Lymphocyte As Myeloma-Initiating Cells from B Cell-Derived Induced Pluripotent Stem Cells

The C Loop of Fifth Epidermal Growth Factor-like Domain of Thrombomodulin Exerts Cytoprotective and Angiogenic Effects in Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only